Search clinical trials for: AG-120

Total 5821 results

Helios Albert-Schweitzer-Klinik Northeim

Completed

Endocuff-assisted Versus Cap-assisted Versus Standard Colonoscopy (EC-Cap-SC)

Colorectal Polyps | Colorectal Adenomas

Germany, Poland
Cerecin

Withdrawn

Medical Food Formulation Pharmacokinetic (PK) Study in Medium Chain Triglycerides

Alzheimer Disease
Stichting Hemato-Oncologie voor Volwassenen Nederland
Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)

Recruiting

A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2

Australia, Austria, Belgium, Estonia, Finland, France, Germany, Ireland, Lithuania, Luxembourg, Netherlands, Norway, Spain, Sweden, Switzerland
Celgene

Active, not recruiting

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

Leukemia, Myeloid, Acute

United States, France, Italy, Korea, Republic of, Spain, United Kingdom, Australia, Canada, Germany, Netherlands, Portugal, Switzerland, Belgium, Sweden
Memorial Sloan Kettering Cancer Center
Agios Pharmaceuticals, Inc.

Recruiting

AG-120 in People With IDH1 Mutant Chondrosarcoma

Chondrosarcoma | IDH1 Gene Mutation | Chondrosarcoma, Grade 2 | Chondrosarcoma, Grade 3

United States
Institut de Recherches Internationales Servier

Recruiting

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Myelodysplastic Syndromes | Relapsed or Refractory Acute Myeloid Leukemia (AML) | Untreated AML | Other IDH1-mutated Positive Hematologic Malignancies

United States, France
Penn State University
Jenny Craig, Inc.

Completed

The Influence of Satiation Measures on the Portion Size Effect

Feeding Behavior

United States
Penn State University

Terminated

The Role of Satiety in the Effect of Portion Size on Intake

Feeding Behavior

United States
Agios Pharmaceuticals, Inc.

Approved for marketing

Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation

Acute Myeloid Leukemia | Relapsed Pediatric AML | Relapsed Adult AML
Vedic Lifesciences Pvt. Ltd.
Enovate Biolife Pvt Ltd

Completed

A Study to Evaluate Efficacy of IP on Alertness and Mental Fatigue (ALERMEN)

Mental Fatigue

India
Groupe Francophone des Myelodysplasies

Active, not recruiting

IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndromes

France, Italy
Agios Pharmaceuticals, Inc.

Completed

Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects

Healthy

United States
Institut de Recherches Internationales Servier

Completed

Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) (ClarIDHy)

Metastatic Cholangiocarcinoma | Advanced Cholangiocarcinoma

United States, Spain, Korea, Republic of, Italy, France, United Kingdom
Agios Pharmaceuticals, Inc.

Completed

A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function

Hepatic Impairment

United States
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma and other conditions

United States, Puerto Rico, Australia
Grünenthal GmbH

Completed

A Clinical Study in Healthy Subjects Which Aims to Investigate the Safety, the Tolerability and the Effects of GRT0151Y and How the Compound is Taken up and Excreted From the Body

Acute Pain

France
Institut de Recherches Internationales Servier

Completed

Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

Glioma | Cholangiocarcinoma | Chondrosarcoma | Other Advanced Solid Tumors

United States, France
Agios Pharmaceuticals, Inc.

Completed

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120

Healthy Volunteers

United States
Institut de Recherches Internationales Servier

Active, not recruiting

Study of AG-120 and AG-881 in Subjects With Low Grade Glioma

Glioma

United States
Yale University

Withdrawn

A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Agios Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348

Healthy Volunteers

United States
Molnlycke Health Care AB

Completed

Evaluating the Efficacy of an Absorbent Foam Dressing Containing Silver (Mepilex Ag) Versus the Same Dressing Without Silver Used on Subjects With Venous Leg Ulcers or Mixed Ulcers

Venous Leg Ulcers | Mixed Leg Ulcers

France, Germany, Netherlands, Czech Republic
Agios Pharmaceuticals, Inc.

Completed

A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881

Healthy Male Participants

United States
Agios Pharmaceuticals, Inc.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

Healthy Volunteers | Anemia, Sickle Cell

United States, Spain, Denmark
Agios Pharmaceuticals, Inc.

Completed

Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulations in Healthy Adults

Healthy Volunteers

United States
Clinical Nutrition Research Centre, Singapore

Completed

The Lunch Study: the Combined Effects of Food Texture and Portion Size on Intake

Satiation

Singapore
Institut de Recherches Internationales Servier

Active, not recruiting

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE)

Leukemia, Myeloid, Acute | Untreated AML | Newly Diagnosed Acute Myeloid Leukemia (AML) | AML Arising From Myelodysplastic Syndrome (MDS)

Spain, United States, France, Korea, Republic of, Taiwan, Australia, Canada, Germany, China, Italy, Austria, Czechia, Poland, Japan, United Kingdom, Russian Federation, Netherlands, Brazil, Israel, Mexico
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

United States, Canada
Yonsei University

Completed

Lower Femtosecond Laser Energy Levels Lead to Better Visual Recovery After Small-incision Lenticule Extraction for Myopia

Myopia

Korea, Republic of
Kala Pharmaceuticals, Inc.

Completed

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation (Hawaii-1)

Ocular Infections, Irritations and Inflammations

United States
Hospital General Universitario Elche

Unknown

RYGB AL 150cm BPL 100cm vs RYGB AL 100cc BPL 150cm

Weight Loss
Joint Authority for Päijät-Häme Social and Health...

Recruiting

Recognition and Treatment of Dysglycemia. AGS - Acute Glucose Service (AGS)

Arthroplasty Complications | Dysglycemia

Finland
Agios Pharmaceuticals, Inc.

Terminated

A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma

Lymphoma

United States
Agios Pharmaceuticals, Inc.

Completed

A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants

Healthy Volunteers

United States
Celgene

Completed

Radiolabeled Study of AG-221 in Healthy Male Subjects.

Healthy Volunteers
Agios Pharmaceuticals, Inc.

Completed

Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Healthy Subjects of Japanese Origin and Non-Asian Origin

Healthy | Japanese | Non-Asian

United States
Ahn-Gook Pharmaceuticals Co.,Ltd
Hanyang University; Ewha Womans University; Konkuk University Medical Center; Kyunghee... and other collaborators

Completed

Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "AG NPP709 Syrup"

Bronchitis | Acute Upper Respiratory Tract Infections

Korea, Republic of
UroGen Pharma Ltd.

Completed

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

Neoplasms | Urologic Diseases | Urinary Bladder Diseases | Bladder Cancer

Israel
Celgene

Completed

PK and Safety Study of AG-221 in Healthy Male Japanese Subjects and Healthy Male Caucasian Subjects

Healthy

United States
Pfizer

Terminated

A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration

Age-Related Macular Degeneration

United States, United Kingdom, Australia, Netherlands
DermBiont, Inc.

Recruiting

A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Dermatosis Papulosa Nigra (DPN)

Dermatosis Papulosa Nigra

United States
Molnlycke Health Care AB

Recruiting

Performance and Safety of Exufiber Ag+ and Exufiber on Partial Thickness Burns

Partial-thickness Burn

United States
Agios Pharmaceuticals, Inc.

Active, not recruiting

A Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Myelodysplastic Syndromes

Israel, United States, Korea, Republic of, Australia, France, Germany, Spain, United Kingdom, Czechia, Austria, Italy, Greece, Poland
Coloplast A/S

Completed

Biatain Ag vs Biatain in the Treament of Leg Ulcers

Leg Ulcers
Brigham and Women's Hospital
Medline Industries

Completed

Evaluation of Opticell Ag on Split-Thickness Skin Graft Donor Sites in Adult Subjects (STSG)

Split-thickness Skin Graft Donor Sites
Agios Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult Participants

Healthy Volunteers

United States
Karl Landsteiner University of Health Sciences
Ludwig Boltzmann Gesellschaft

Not yet recruiting

The Effectiveness of a Serious Game Targeting Interpersonal Emotion Regulation in Early Adolescents

Interpersonal Relations
The University of Texas Medical Branch, Galveston

Withdrawn

PermeaDerm® vs. Mepilex-Ag® in Promoting Healing of Partial-thickness Burn Wounds

Partial-thickness Burn

United States
University of Wisconsin, Madison

Terminated

BinaxNOW for Evaluating Children for Infection With SARS-CoV-2 (COVID-19)

COVID-19 | SARS-CoV2 Infection

United States
Groupe Francophone des Myelodysplasies

Active, not recruiting

IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia Acute Myeloid

France

Search clinical trials for: AG-120

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations